Quanterix Corporation

QTRX

Equity

ISIN null / Valor 39127916

NASDAQ (2025-11-21)

USD 6.66+12.7%

Quanterix Corporation
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Quanterix Corporation is a company focused on transforming healthcare by enhancing the precision and understanding of health to disease progression through advanced scientific research. It operates at the forefront of the healthcare industry, leveraging a combination of experienced management, leading scientists, and strategic investments to push the boundaries of precision health science. The company has established a significant global presence, serving hundreds of academic and industry clients with direct sales in North America and parts of Europe, while also reaching a wider international market through distributor partnerships. Quanterix offers a range of products and services designed to support the research needs of its customers, backed by a dedicated team of field application scientists and engineers providing comprehensive customer support worldwide. This approach underscores the company's commitment to advancing healthcare research and diagnostics through innovative technology and collaborative efforts.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Decline

In the first quarter of 2025, Quanterix Corporation reported revenues of $30.3 million, marking a 5% decrease from $32.1 million in the same period last year.

Gross Margin Reduction

The GAAP gross margin for the quarter was 54.1%, down from 57.8% in the prior year. Adjusted gross margin (non-GAAP) also declined to 49.7% from 51.2% year-over-year.

Increased Net Loss

Quanterix experienced a net loss of $20.5 million in Q1 2025, which is a rise from a net loss of $11.2 million in the first quarter of 2024.

Strong Cash Position

The company ended the quarter with $269.5 million in cash, cash equivalents, marketable securities, and restricted cash, despite a use of approximately $22 million in cash.

Cost Reduction Initiatives

Quanterix is implementing targeted cost reductions of about $30 million annually to navigate market headwinds and streamline its integration with Akoya Biosciences, aiming to generate positive cash flow by 2026.

Operational Advancements

The company launched a new early-access program for Simoa® ONE assay kits, expanded its assay portfolio with a dried blood spot extraction kit, and amended its merger agreement with Akoya Biosciences to enhance shareholder value.

2025 Full Year Outlook

For the full year 2025, Quanterix expects revenues between $120 million to $130 million and anticipates achieving positive cash flow by 2026 through disciplined financial strategies and continued innovation.

Summarized from source with an LLMView Source

Key figures

-43.2%1Y

-44.1%3Y

-85.5%5Y

Performance

81.4%1Y

71.8%3Y

83.6%5Y

Volatility